首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Lancet Haematology

Lancet Haematology杂志,由Lancet Publishing Group出版,于2014年创刊,12 issues/year,出版语言English,ISSN:2352-3026。

投稿咨询
Lancet Haematology
Lancet Haematology
Lancet Haematology
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
20.4
CiteScore
29.4
期刊收录
SCI、SCIE

Lancet Haematology(中文译名:《柳叶刀血液学》),ISSN:2352-3026,是Lancet Publishing Group出版的国际性学术期刊,创刊于2014年,以12 issues/year形式稳定发行,2026年总发文量约69篇。该刊采用非OA开放访问,学科归属为HEMATOLOGY。该刊是医学、血液学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达20.4,2025年期刊CiteScore为29.4,2025年期刊自引率约2%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Lancet Haematology长期聚焦医学、血液学及相关产业的技术应用前沿,在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、血液学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAEngland、Italy、France、Netherlands、GERMANY (FED REP GER)、Spain等为核心发文国家与地区;ASSISTANCE PUBLIQUE HOPITAUX PARIS (APHP)UNIVERSITY OF LONDON、UNIVERSITY OF TEXAS SYSTEM、HARVARD UNIVERSITY、UNIVERSITE DE PARIS、DANA-FARBER CANCER INSTITUTE、INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学
1区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学
1区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学
1区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 3 / 103

97.6

学科:HEMATOLOGY SCIE Q1 2 / 103

98.54

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 4 / 97

96.4

学科:HEMATOLOGY SCIE Q1 3 / 97

97.42


中国学者近期发文

1
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VT

Author:Cheng, Zhang; Jin, Yiqi

Journal: LANCET HAEMATOLOGY. 2026; Vol. 13, Issue 3, pp. e124-e124. DOI:

2
Low-dose moderate hypofractionated radiotherapy for indolent non-Hodgkin lymphoma: a multicentre, single-arm, phase 2 tria

Author:Wang, Xin-Yue; Zhang, Xi-Mei; Wang, Liang; Gao, Lin-Rui; Chen, Ke; Feng, Xiao-Li; Rao, Wei; Zheng, Rong; Wu, Yun-Peng; Song, Yong-Wen; Fang, Hui; Chen, Bo; Jin, Jing; Liu, Yue-Ping; Jing, Hao; Tang, Yuan; Zhang, Wen-Wen; Zhai, Yi-Rui; Lu, Ning-Ning; Li, Ning; Xia, Chang-Fa; Wang, Shu-Lian; Liu, Xin; Li, Ye-Xiong; Qi, Shu-Nan

Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 6, pp. e442-e450. DOI: 10.1016/S2352-3026(25)00071-7

3
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitor

Author:Risitano, Antonio M.; Kulasekararaj, Austin G.; Scheinberg, Phillip; Roeth, Alexander; Han, Bing; Maciejewski, Jaroslaw P.; Ueda, Yasutaka; de Castro, Carlos M.; Di Bona, Eros; Fu, Rong; Zhang, Li; Griffin, Morag; Langemeijer, Saskia M. C.; Panse, Jens; Schrezenmeier, Hubert; Barcellini, Wilma; Mauad, Vitor A. Q.; Schafhausen, Philippe; Tavitian, Suzanne; Beggiato, Eloise; Chew, Lee Ping; Gaya, Anna; Huang, Wei-Han; Hojang, Jun; Kitawaki, Toshio; Kutlar, Abdullah; Notaro, Rosario; Pullarkat, Vinod; Schubert, Joerg; Terriou, Louis; Uchiyama, Michihiro; Lee, Lily Wong Lee; Yap, Eng-Soo; Frieri, Camilla; Marano, Luana; de Fontbrune, Flore Sicre; Gandhi, Shreyans; Trikha, Roochi; Alashkar, Ferras; Yang, Chen; Liu, Hui; Kelly, Richard J.; Hoechsmann, Britta; Lawniczek, Tomasz; Mahajan, Navin; Solar-Yohay, Susan; Kerloeguen, Cecile; Ferber, Philippe; Kumar, Rakesh; Wang, Zhixin; Thorburn, Christine; Maitra, Samopriyo; Li, Shujie; Verles, Aurelie; Dahlke, Marion; de Latour, Regis Peffault

Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 6, pp. e414-e430. DOI:

4
Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancie

Author:Broeckelmann, Paul J.; Cliff, Edward R. Scheffer; Iacoboni, Gloria; Simon, Florian; Horowitz, Mary M.; Keating, Armand; Mateos, Maria-Victoria; Mohty, Mohamad; Sidana, Surbhi; Song, Yuqin; Wingard, John R.; Thanarajasingam, Gita

Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 6, pp. e470-e481. DOI: 10.1016/S2352-3026(25)00051-1

5
Anti-GPRC5D CART-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CART-cell therapy: a single-centre, single-arm, phase 2 tria

Author:Xia, Jieyun; Sun, Qian; Zhou, Dian; Li, Hujun; Wang, Ying; Qi, Yuekun; Cao, Jiang; Yan, Zhiling; Li, Depeng; Cheng, Hai; Sang, Wei; Zhu, Feng; Sun, Haiying; Chen, Wei; Qi, Kunming; Yan, Dongmei; Qiu, Tingting; Hu, Tingyu; Gu, Weiying; Qian, Jun; Xia, Fan; Qi, Na; Jin, Congqian; Liu, Yang; Wang, Xue; Zhang, Yanlei; Peng, Shuixiu; Li, Zhenyu; Chang, Alex H.; Xu, Kailin

Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 5, pp. e365-e375. DOI: 10.1016/S2352-3026(25)00048-1

6
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 stud

Author:Zhao, Xin; Sun, Jing; Zhang, Zhihua; Chen, Miao; Gong, Tiejun; He, Guangsheng; Li, Yingmei; Liu, Hong; Li, Fei; Li, Xin; Zhou, Hu; Wang, Xiaoqin; Hong, Mei; Lei, Lei; Yin, Hongyan; Luo, Xian; Li, Yang; Fan, Songhua; Guo, Xiaojun; Shi, Michael M.; Su, Weiguo; Zhang, Liansheng; Han, Bing; Zhang, Fengkui

Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 2, pp. e97-e108. DOI: 10.1016/S2352-3026(24)00344-2

7
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre single-arm, phase 2 tria

Author:Alderuccio, Juan Pablo; Alencar, Alvaro J.; Schatz, Jonathan H.; Kuker, Russ A.; Pongas, Georgios; Reis, Isildinha M.; Lekakis, Lazaros J.; Spiegel, Jay Y.; Sandoval-Sus, Jose; Beitinjaneh, Amer; Stanchina, Michele D.; Trabolsi, Asaad; Lossos, Izidore S.; Rosenblatt, Joseph D.; Lessen, David S.; Moskowitz, Craig H.

Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 1, pp. e23-e34. DOI: 10.1016/S2352-3026(24)00345-4


在线咨询

Lancet Haematology

国际简称:LANCET HAEMATOL参考译名:柳叶刀血液学

年发文量:69 CiteScore:29.4 是否预警:否 Gold OA文章占比:11.88% 研究类文章占比:82.61%

杂志社联系方式:THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OXON, OX5 1GB

Lancet Haematology